The inability of pharmacologically based therapeutic molecules, such as the cholinesterase inhibitors and memantine, to effectively prevent clinical deterioration in Alzheimer's disease (AD) over the long term has stimulated the search for more effective therapeutic approaches that may have the ability to show significant disease-modifying activity. Immunotherapeutic approaches are perhaps the most exciting potential therapeutic options on the near horizon. The most closely watched therapeutic approaches falling into this class that may become available in the reasonably near term include: two experimental therapeutics designed to directly attack A-beta, AAC-001 and bapineuzumab; another immunotherapeutic whose mechanism of action is still being delineated, but which also contains anti-amyloid antibodies, namely intravenous immunoglobulin; and a fourth therapeutic, which, although it may address certain amyloid-mediated mechanisms, takes a completely novel therapeutic approach to treating AD, namely peri-spinal etanercept.
There has been considerable interest in AAC-001 (clinicaltrials.gov identifier NCT00498602), which is an active antiamyloid vaccine undergoing clinical trial testing by Elan/Wyeth. It is a modified version of AN-1792, 2 a previous anti-amyolid vaccine tested several years ago by this same consortium, but whose clinical development was stopped because of severe meningoencephalitis that occurred in 18 of 300 study participants. there is the possibility that testing will resume.
Passive Anti-amyloid Immunotherapy with Bapineuzumab
Bapineuzumab is a humanized monoclonal antibody to A-beta being developed by Elan/Wyeth. 4 The rationale is that passive A-beta antibodies may have the potential to bind and reduce brain A-beta. Bapineuzumab is currently being trialed in two separate studies in patients with probable AD: one for ApoE4-positive carriers and one for ApoE4-negative carriers.
These studies are both for selected participants with mild to moderate AD with MMSE scores ranging from 16 to 26. The study of ApoE4-positive carriers (clinicaltrials.gov identifier NCT00575055) is planned to include 800 enrollees. The ApoE4 negative carrier study (clinicaltrials.gov identifier NCT00574132) is planned to include 1,250 enrollees at 200 study sites.
Both trials were begun in December 2007 and are scheduled for completion in December 2010 (the final data collection date for the primary outcome measure).
These are placebo-controlled studies; the active comparator will consist of 0.5mg/kg infusions given over a period of 60 minutes every 13 weeks for a total of 18 months for the ApoE4-positive patients, and doses of 0.5, 1.0, or 2.0mg/kg (three groups) for the ApoE4-negative patients.
There is some concern regarding the risk of brain microhemorrhages, which have been seen in transgenic mice treated with passive A-beta vaccines. 5 In a 30-patient randomized, double-blind, placebo-controlled, singleascending-dose trial of bapineuzumab treated with infusions ranging from 0.5 to 5mg/kg, three of 10 patients treated at the 5mg/kg dose developed magnetic resonance imaging abnormalities, consisting predominantly of high signal abnormalities on fluid attenuated inversion recovery sequences, which resolved by 12 weeks post-dose. 4 With multiple doses, one might be concerned that these effects could be augmented. The study designers were apparently more concerned about safety in the ApoE4 positive carriers, hence the reduced dosing levels in these patients. The phase III trials are currently recruiting study participants.
Intravenous Immunoglobulin
Intravenous immunoglobulin (IVIg) is used off-label for a variety of disorders involving neurological inflammation, including myasthenia gravis, certain forms of multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy. 6 In 2002, naturally occurring antibodies directed against A-beta were detected in IVIg preparations and found to be present in both serum and cerebrospinal fluid (CSF) after intravenous infusion. 7 These same investigators later conducted a pilot study utilizing monthly IVIg infusions in five patients with AD treated over six months. A-beta in the CSF decreased by 30% compared with baseline, and the Alzheimer's Disease Asssement Scale-cognitive subscale (ADAS-Cog) improved by 3.7±2.0 points. 8 Scores on MMSE did not show a significant change. 8 Most recently, at the just concluded American Academy of Neurology annual meeting, the results of a placebo-controlled, phase II clinical trial of IVIg for the treatment of 24 patients with probable AD (MMSE [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] was discussed. Subjects received infusions every two to four weeks at dosages ranging from 0.2g/kg/2weeks to 0.8g/kg/month, with assessment of ADASCog and clinical global impression of change (CGIC). 9 IVIg resulted in increased anti-amyloid antibody levels and decreased CSF beta-amyloid. 9 Global outcomes, as measured by CGIC, were slightly improved (0.27 GCIC points for IVIg versus 1.25 for placebo), but ADAS-Cog, although favoring the active group, did not reach statistical significance.
The results were interpreted as encouraging the initiation of a phase III clinical trial. In this trial, the only adverse event that was increased in the active group was skin rash. A review of IVIg therapy reports that most adverse events are mild and transient, but severe adverse reactions can occur. 10 Acute renal failure, usually occurring in the first 10 days after IVIg administration, is usually reversible, and thromboembolic complications are also a risk. 10 As a pooled blood product, there is a small risk of transmission of viral diseases, and hemolytic anemia, death, and transfusion-related acute lung injury have been reported. 10 A phase III clinical trial is scheduled to begin soon.
Peri-spinal Etanercept
Tumor necrosis factor-alpha (TNFα) is a cytokine that is well recognized as a key mechanism of disease. 11 In 1999, excess TNF in the CSF of patients with AD was found at a level 25 times that of controls. 12 Although initially it was thought by the group that made this discovery that TNF was playing a neuroprotective role, they later determined that excess TNF in patients with mild cognitive impairment was associated with progression to AD. 13 The New Horizons in the Treatment of Alzheimer's Disease-Immunotherapeutics
Impact of Increased Life Expectancy on Alzheimer's Disease Death Rate
More women than men have Alzheimer's/other dementias, primarily because on average women live longer than men and their longer life expectancy means females are more susceptible to developing neurological conditions.
Impact of Co-existing Medical Conditions
Most people with Alzheimer's/other dementias have one or more other serious medical conditions. For example, 30% of Medicare beneficiaries aged 65 years and over with Alzheimer's/ other dementias also have coronary heart disease, while 28% have congestive heart failure.
However, deaths from diseases such as heart disease and cancer are declining, which, since 2000, has led to an increase in Alzheimer's disease death rates for the oldest age groups. 
